Account
Insider Insights
17.02.2022
Analysis of top ten therapeutic groups dispensed

In terms of volume, proton pump inhibitors were the top-selling therapeutic group (at ATC-level 4) w...

Read more
Insider Insights
17.02.2022
Paracetamol and Ibuprofen combination available

The switch from prescription to non-prescription status was recommended by the Federal Institute for...

Read more
Insider Insights
16.02.2022
AIFA announces reimbursement of oral SMA treatment

The Italian Medicines Agency (AIFA) has announced that Roche’s Evyrsdi (risdiplam) is reimbursed w...

Read more
Insider Insights
15.02.2022
NICE recommends CDF use of dostarlimab

The CDF allows patients to access a new treatment while further data is collected on its clinical an...

Read more
Insider Insights
14.02.2022
Fall in wholesale margins on prescription drugs

Wholesale margins on prescription drugs fell to 3.99% in 2021 (down from 4.09% in the previous year)...

Read more
Insider Insights
10.02.2022
Institute of Cancer Research labels NICE

In a statement the ICR said that it welcomes some of the changes, but that it wants to “see furthe...

Read more
Insider Insights
10.02.2022
Reimbursement rate of gliptins revised downwards

In line with legislation published in the Official Journal (Journal Officiel) on 1st February 2022, ...

Read more
Insider Insights
09.02.2022
CMA fines firms 35 million

The actions of the companies meant that from December 2013 to December 2017, the price paid by the N...

Read more
Insider Insights
07.02.2022
NHS England announces access deal for Libmeldy

The news comes after the health service negotiated a “significant confidential discount” to the ...

Read more
Insider Insights
01.02.2022
UK NICE recommends selective laser therapy

According to updated guidelines published by NICE, patients newly diagnosed with glaucoma and ocular...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.